Cormorant Asset Management’s Crescent Biopharma CBIO Stock Holding History

Cormorant Asset Management’s Portfolio CBIO Stock Details CBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-2,870	Closed	-$1.56M	–	75
2017 Q1	$1.56M	Hold	2,870	–	–	0.23%	65
2016 Q4	$1.75M	Hold	2,870	–	–	0.24%	64
2016 Q3	$2.05M	Hold	2,870	–	–	0.23%	65
2016 Q2	$2.09M	Buy	2,870 +34	+1%	+$23.4K	0.3%	60
2016 Q1	$1.69M	Hold	2,836	–	–	0.25%	64
2015 Q4	$1.62M	Sell	2,836 -1,754	-38%	-$1.16M	0.19%	64
2015 Q3	$2.57M	Hold	4,590	–	–	0.41%	54
2015 Q2	$3.65M	Hold	4,590	–	–	0.49%	48
2015 Q1	$3.82M	Sell	4,590 -133	-3%	-$103K	0.59%	46
2014 Q4	$3.4M	Hold	4,723	–	–	0.52%	46
2014 Q3	$3.28M	Hold	4,723	–	–	0.67%	40
2014 Q2	$3.98M	Buy	4,723 +29	+0.6%	+$28.9K	1.05%	38
2014 Q1	$7.67M	Buy	+4,694	New	+$5.68M	1.76%	25

Other funds holding CBIO

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Cormorant Asset Management's CBIO Position: Q2 2017 in Review

Cormorant Asset Management sold out of Crescent Biopharma (CBIO) in Q2 2017, closing a stake of 2,870 shares — an estimated $1.56M sold.

Cormorant Asset Management first reported a position in CBIO in Q1 2014 and held it in 13 quarters. The position peaked at $7.67M in Q1 2014. 69 funds tracked by Wall St. Rank hold CBIO as of Q2 2017.

Cormorant Asset Management reported no remaining Crescent Biopharma position as of Q2 2017 after selling out during the quarter.
Cormorant Asset Management sold 2,870 Crescent Biopharma shares in Q2 2017, an estimated $1.56M.
Cormorant Asset Management first reported a position in Crescent Biopharma in Q1 2014 and held it in 13 quarters.
Cormorant Asset Management's Crescent Biopharma position peaked at $7.67M in Q1 2014.
69 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2017.

Based on Cormorant Asset Management's 13F filing for Q2 2017, filed 14 Aug 2017.